Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 6 · below the Ichimoku cloud · RSI 44 · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in EFTR in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EFTR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for EFTR.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 200.0 | 0.0 | 0.0 | -66.7 | 50.0 | -33.3 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 50.0 | -33.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | -1.8 | 25.9 | -0.3 | -84.4 | -28.9 | -81.9 | -86.1 | -0.7 | -7.5 | -98.9 | -50.0 | 0.0 | −100.0% |
| 2023 | 20.0 | -2.9 | -29.2 | 33.3 | 97.9 | -10.7 | -2.6 | -9.9 | -17.6 | -10.0 | -1.8 | -11.9 | +9.3% |
| 2022 | -31.8 | -17.7 | -13.8 | -17.0 | -35.1 | -34.3 | -43.0 | -24.7 | -6.1 | 7.1 | -31.5 | 1.9 | −94.8% |
| 2021 | 26.6 | -28.9 | -34.1 | 25.8 | −25.4% |
No analyst coverage for this instrument.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
No recent headlines.